Home/ Stocks/ SPRY

ARS Pharmaceuticals, Inc. Common Stock

SPRY XNAS

$6.16 +0.54 (+9.82%) ▲ 15-min delayed

Open

$5.60

High

$6.16

Low

$5.58

Volume

2.16M

Market Cap

$551.13M

About ARS Pharmaceuticals, Inc. Common Stock

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 159 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$22.68M	$-60,618,000	$-0.61
FY 2025	$84.28M	$-171,298,000	$-1.74
Q3 2025	$32.50M	$-51,151,000	$-0.52
Q1 2025	$7.97M	$-33,940,000	$-0.35

Related Market News

No specific coverage for SPRY yet. Check out our latest market news or earnings calendar.

Get SPRY Alerts

Stay ahead with breaking news, price alerts, and expert analysis on ARS Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.